SR&ED’s Pre-Claim Approval and what Actually Matters for Founders

Last week, Canada passed the most significant updates to the SR&ED program in over a decade. After years of advocacy from many groups and Canadian leaders, major reforms to Canada’s Scientific Research and Experimental Development (SR&ED) program take effect today.

You’ve likely already seen the headlines and all the "hot takes" but the real question is what these changes mean for how you build your company.

For years, SR&ED hasn’t kept pace with how modern companies operate. Limits didn’t move with inflation, capital-heavy innovation was at a disadvantage, and many companies outgrew the program earlier than they should have. What we’re seeing now is less about generosity and more about the government catching up.

Arguably the most active group in pushing for these updates is the Canadian Council of Innovators and as members of CCI, we’ve had a front-row seat to many of the conversations shaping these changes.

The direction is clear: this is about making SR&ED more relevant to how companies actually build today.

The Updates

On paper, the changes are straightforward:

• capital expenditures are eligible again,
• expenditure limits for CCPCs have doubled from $3M to $6M,
• taxable capital thresholds have expanded,
• and certain public companies can now access refundable credits (Canadian-listed firms, that are Canadian-controlled and their Canadian-based subsidiaries)

Individually, these look like incremental improvements. Taken together, they materially increase the amount of non-dilutive capital available to innovative companies.

For some businesses, refundable SR&ED can now reach over $2M annually. That’s no longer a marginal benefit, it’s meaningful runway.This shift also changes who benefits most. Bringing capital expenditures back into the program is particularly significant for companies investing heavily in infrastructure, equipment, or technical systems. Hardware, manufacturing, and deep tech businesses, historically disadvantaged under SR&ED, are now much better positioned to benefit. At the same time, higher limits and expanded eligibility mean the program extends further into the growth stage, and the belief that this is just for "early stage" companies can be rebutted.

I think these changes should change behaviour in material way.

The Mindset Shift

Historically, SR&ED has been treated by most companies as a retrospective exercise. You build, you document, and you file. You optimize around the edges.

We tell our customers (and have been for some time!) that this is an outdated and ineffective approach.  And now, when the program becomes this material, and when capital and scale are more meaningfully included, it starts to influence decisions upstream. Hiring plans, technical direction, capital allocation, and the timing of investment all become part of the equation. SR&ED moves from something you deal with after the fact to something you can design around and plan for in a strategic way.

New: The Pre Claim Approval Process

One area where we see a lot of optimism, and where we take a more cautious view, is in the new Pre-Claim Approval process (PCA). In theory, this offers certainty before work begins, along with faster processing and reduced audit risk. On the surface, that’s appealing. But innovation rarely follows a fixed path.

Projects evolve, scope shifts, and technical challenges change direction. Locking in assumptions early may limit flexibility later, whether that means under-claiming or constraining how work develops. Certainty has value, but in this context, it might come at a cost. For many companies, especially those iterating quickly, flexibility could bemore important.That doesn’t mean pre-claim approvals won’t have a place. It does mean they should be approached thoughtfully, not automatically and we will continue to watch this space.

Final Thoughts

Overall, the risk is that companies interpret these changes too narrowly. It’s easy to see this as simply “more funding” or a larger claim opportunity. In reality, the bigger shift is strategic.

SR&ED is no longer just about maximizing what you did, it’s increasingly about shaping what you choose to do.The companies that benefit most won’t be the ones that file the "best" claims. They’ll be the ones that plan more deliberately, align their technical and financial decisions earlier, and treat SR&ED as part of how they build, not just how they report.

I think we can all agree that the Canadian government has made it easier to fund innovation with these updates. This is a meaningful step forward but it doesn’t change the fundamentals. Building a great company still comes down to execution, judgment, and timing. These program improvements have been a long time coming and as CCI noted, "now the focus is on making sure it works in practice and continues to improve."

SR&ED is a more powerful tool than it was before. What matters is how you choose to use it.

‍

The build vs. buy decision in non-dilutive funding

Managing non-dilutive funding internally requires a trade-off between saved fees and lost engineering velocity. While the "0% fee" of a Do-It-Yourself (DIY) approach is appealing, it often fails to account for the substantial internal cost of diverted technical talent and the unhedged risk of compliance reviews. This decision is rarely just about the invoice at the end of the process; it is a calculation of internal hours versus the value of specialized expertise in maximizing claim size and defensibility.

For the busy executive, the instinct to keep the process in-house typically stems from a mandate to preserve cash flow and reduce administrative overhead. However, treating the annual SR&ED tax credit or any number of grant applications as a purely administrative task underestimates the technical rigour required by the Canada Revenue Agency (CRA) for SR&ED and various funding bodies (for grants).

When technical leaders divert their focus from product development to writing and compliance, the company incurs a hidden cost that does not appear on a balance sheet but impacts the product roadmap significantly.

We view this as an engineering resource allocation problem rather than a simple accounting decision. You must weigh the certainty of professional fees against the variable and often higher costs of internal time, potential claim reductions, and the significant disruption of a defensibility audit. The pragmatic approach involves analyzing where your team adds the most value: writing code that generates revenue or writing technical narratives to reclaim costs.

The math: Internal engineer hours vs. Agency fees

Quantifying the true cost of a DIY claim reveals that a robust filing typically costs $12,000+ in direct engineering time plus significant opportunity costs, often exceeding the perceived savings of avoiding agency fees. A defensible claim typically requires 40–80 hours of time from senior technical leaders, such as the Chief Technology Officer (CTO) or Vice President (VP) of Engineering, to scope projects and draft narratives that meet legislative requirements.

Calculating opportunity cost

If a CTO spends 80 hours on claim preparation and compliance, they are not shipping product. With an estimated internal cost of $150/hour for senior engineering time, the direct investment is $12,000. However, this figure only accounts for the base salary and overhead. It does not factor in the context switching required to move from high-level architecture or team management to retrospective technical documentation.

The indirect cost, lost velocity on the roadmap, can be significantly higher.

When a technical lead pauses development to compile timesheets, comb git commits for evidence, and draft technical narratives, the entire engineering team may experience a slowdown. In a fast-moving market in 2026, delaying a feature release by two weeks to accommodate a tax filing deadline can result in missed market opportunities that far exceed the cost of the filing itself.

On the grant side of things, we see that often poor ROI on successful grants can be associated with internal attempts, where high-value hours are spent on low-leverage administrative drafting rather than core innovation.

Comparing the agency model

Consultants typically charge a success-based fee ranging from 10% to 20% of the claim value. This model aligns incentives: the partner is paid only when funding is received, offloading 80–90% of the heavy lifting. By engaging an advisory partner, the internal time commitment often drops to 5-10 hours of document gathering, high-level interviews and reviews. The advisor handles the labour-intensive tasks of mapping financial data to technical activities and ensuring the language meets specific CRA criteria.

The reality of "free" filings

There is no such thing as a free claim. You are either paying an external expert from the refund or funding the process with expensive, pre-tax engineering payroll. When companies attempt to save the advisory fee, they often effectively "pay" that amount or more through inefficient internal processes. Furthermore, internal teams lacking specialized knowledge may inadvertently leave eligible expenditures unclaimed, effectively paying an "ignorance tax" that reduces the net benefit of the program.

The risk: Audit risk in non-dilutive funding

Compliance exposure is the single largest variable that DIY cost models fail to capture, with anecdotal industry data suggesting significant review and audit rates for Scientific Research & Experimental Development (SR&ED) claims.

While being selected for a review is not necessarily an indication of wrongdoing, it is a procedural reality that demands significant time and resources to manage.

The cost of defence

Defending a claim without support is a massive distraction. A typical review process can require 200+ hours of preparation, evidence gathering, and meetings with CRA officials. This "distraction tax" can paralyze a technical team for months. The CRA review process involves deep dives into technical obstacles, contemporaneous evidence, and financial allocations. Without a partner to filter requests and organize data, the technical team must educate themselves on tax law in real-time while trying to defend their engineering work.

Advisory insulation

Firms that employ ex-CRA auditors build defence into the process from day one. By preparing claims that anticipate specific  SR&ED advisory services  triggers, they reduce the likelihood of extensive inquiries. An experienced advisor understands how to frame "technological uncertainty" and "systematic investigation" in ways that align with  Section 37 of the Income Tax Act , which governs the eligibility of scientific research and experimental development.

Pricing the risk

When making the decision, you must price in the probability of a significant time penalty.  CRA program service standards  indicate that refundable claims selected for review are processed within 180 days, but the internal disruption can last much longer. For a company focused on cash flow, the delay in funding combined with the resource drain of a defence can be damaging. An advisory partner provides a layer of predictability, ensuring that if a review happens, it is a managed process rather than a crisis.

Next step: Review your past three filings for documentation gaps that could trigger a compliance review.

The hidden friction of DIY compliance

Issues with retroactive documentation is the primary cause of claim denial and compliance issues, as the CRA expects evidence generated at the time the work was performed rather than reconstructed logs. DIY teams often scramble to reconstruct logs at year-end, a practice that creates inconsistencies during reviews and weakens the defensibility of the claim.

Best practice is to gather evidence at the time the work is performed. Your advisors can recommend ways to implement systems to capture this evidence throughout the year, ensuring data is defensible by default. Relying on git commit logs or Jira tickets alone is often insufficient; the CRA looks for evidence of the process of experimentation, such as hypothesis testing, analysis of failures, and iterative conclusions.

Navigating government funding rules

Stacking funding requires precision. For example, understanding how the Industrial Research Assistance Program (IRAP) interacts with tax credits is critical. Misclassifying "government funding" or failing to account for it correctly can lead to accidental double-dipping and mandatory repayments. Distinguishing between "government assistance" (which grinds down your SR&ED claim) and a "bona fide loan" (which typically does not) is a technical distinction with massive financial implications.

Systematic evidence gathering

Experienced advisors transform compliance from a year-end panic into a background process. This ensures that if a review happens, the data is already organized and prepared for review. By integrating funding strategy into the company's operational rhythm, the "tax season" becomes a review of existing documentation rather than a creation of new documents.

Next step: Implement a monthly technical meeting log to capture contemporaneous evidence of hypotheses and failures.

Securing capital without stalling the roadmap

Non-dilutive funding should serve as fuel for your innovation, not a brake on your development velocity. The goal is to capitalize the company and protect your cap table while keeping your most valuable assets, your engineers, focused on solving technical problems. Choosing an advisory partner brings the "adult in the room" to your funding strategy, replacing guesswork and retroactive scrambling with predictability, stability, and a process that preserves your equity.

When you calculate the cost of lost engineering hours, the risk of a 200-hour audit defence, and the potential for missed funding opportunities, the "savings" of a DIY approach often evaporate. A strategic partnership allows you to maximize your non-dilutive intake while maintaining the focus required to grow your business.

If your R&D expenditures are scaling, it is time to evaluate whether your current filing method is costing you more than you realize.  Book a discovery call to audit your funding strategy  and discuss how to maximize your return while minimizing your risk.

FAQs

Q: What is the typical success fee for an SR&ED consultant?

A: Fees generally range from 10-20% of the approved claim. This model ensures the partner is only compensated when you successfully receive funding.

Q: Does hiring a consultant guarantee I won't be audited?

A: No partner can guarantee a zero-audit rate, as the CRA uses random selection alongside risk-based selection. However, working with a firm that utilizes ex-CRA auditors ensures your claim is constructed to minimize compliance inconsistencies and that you have professional representation if a review occurs.

Q: Can I just write the technical part and hire an accountant for the numbers?

A: Similar to building a product without a blueprint, this hybrid approach creates risk. A common cause for reviews is a misalignment between the technical narrative and the financial schedules. An integrated partner ensures these two halves of the claim tell a consistent story, preventing discrepancies that trigger reviews.

Q: How much time does my engineering team need to commit if we use an advisor?

A: A streamlined advisory process typically requires some up front work in the first year from your technical lead for interviews and final review, and less as subsequent years go by. This is compared to the 40–80 hours required for a DIY filing. This allows your senior technical talent to remain focused on product development.

Please note that this content is for general informational purposes only and does not constitute tax or legal advice. We hope this analysis provides a helpful overview for founders navigating the 2026 funding landscape.

‍

‍

Non-dilutive funding provides a strategic bridge by offering predictable liquidity that preserves equity during a market correction. By decoupling runway from valuation, founders can utilize tax credits and government funding to reach commercial milestones without suffering the excessive dilution of raising capital in a liquidity-constrained environment.

Canadian venture capital trends 2026: Liquidity drought and capital concentration

The current liquidity drought, driven by a consolidation of capital into a few major funds, forces founders to look beyond equity for survival. According to recent  Canadian Venture Capital and Private Equity Association (CVCA) market reports , a significant majority of available capital has consolidated into a handful of large Venture Capital (VC) funds. This concentration leaves most founders outside of these specific networks with limited equity options.

Exit activity has remained quiet with a continued Initial Public Offering (IPO) drought and limited Mergers and Acquisitions (M&A) deals, which has materially impacted the 10-year internal rate of return for investors. Without exits generating returns, Limited Partners (LPs), the investors backing VC funds, cannot recycle capital back into the ecosystem. This breaks the flywheel of venture financing, leading investors to become risk-averse and focus on consensus-driven bets.

The plight of the emerging manager

Emerging managers are struggling to raise capital, which creates a specific funding gap for seed and pre-seed companies that historically rely on these early believers. While established firms continue to deploy capital into later-stage companies, the "missing middle" of the market is widening.

Emerging managers are often the first institutional check for a startup, bridging the gap between angel rounds and Series A. However, with LPs retreating to safer, established asset classes, these smaller funds have less dry powder to deploy. This reduction in active early-stage funds leads to fewer diverse bets being made, requiring founders to demonstrate stronger traction metrics earlier in their lifecycle to secure equity from the remaining active players such as established early-stage venture funds.

The rise of venture debt and non-dilutive funding

Venture debt and government funding are shifting from supplementary capital to primary liquidity mechanisms for extending runway in 2026. This trend indicates that founders are increasingly utilizing non-dilutive instruments to extend runway without impacting their cap tables during valuation compressions.

The market has seen a pivot toward debt instruments. Major lenders and specialized legal firms are seeing increased activity as founders seek "bona fide loans" to finance operations. It is important to note the technical distinction here: bona fide loans generally do not reduce your Scientific Research & Experimental Development (SR&ED) tax credit entitlement, whereas government funding (grants) typically does reduce your eligible cost base.

Furthermore, federal investments into programs such as the National Research Council's Industrial Research Assistance Program (NRC IRAP) continue to support defence and dual-use technologies. By utilizing these domestic programs, companies can secure Canadian Dollars (CAD) that do not dilute ownership.

Prepare a pre-assessment: Review your eligibility for government funding programs to supplement your capital stack before initiating your next equity raise.

Non-dilutive funding vs. equity: Strategic considerations for 2026

Founders must weigh the cost of capital against the administrative requirements of compliance when choosing between equity and non-dilutive sources. While equity provides "no-strings" cash in exchange for long-term ownership, non-dilutive funding requires rigorous adherence to technical documentation and eligibility criteria.

In 2026, the strategic advantage lies in retaining control. Non-dilutive funding allows founders to finance R&D without surrendering board seats or voting rights during a period where valuations are depressed. However, this capital is not "free"; it demands a commitment to internal processes. Founders must treat their compliance obligations with the same seriousness as investor relations. The trade-off is clear: invest time in documentation now to preserve equity value for the future.

Navigating the Canadian funding ecosystem: key players and advisory hubs

Early stage Founders must navigate a complex ecosystem comprising institutional lenders, specialized banks, and innovation hubs to build a complete capital stack. Understanding the distinct roles of these organizations can help founders identify the right partners for their specific growth stage.

• Institutional and banking support: Founders should evaluate services from national development banks, which often offer venture loans and convertible notes tailored for scaling technology companies. Similarly, major innovation banking divisions within Canadian financial institutions provide specialized debt facilities for high-growth startups.

• Advisory and capital markets: For later-stage needs, engaging an investment bank can assist with capital markets advisory and M&A. Founders looking for alternative models might explore revenue-based financing providers which are particularly effective for e-commerce and SaaS companies with strong sales metrics. Equity crowdfunding platforms also offer ways to diversify capital access.

• Innovation hubs: Ecosystem partners such as major university incubators and regional accelerators serve as vital advisory hubs. These organizations prepare founders for fundraising diligence and often act as the first line of support in connecting startups with available funding.

An integrated approach that manages both tax incentives and grants is superior to siloed services because it prevents conflicting strategies and maximizes net cash flow. As venture debt Canada growth accelerates, selecting a fundraising advisory boutique requires partners who understand the interplay between different funding sources.

For the busy Founder or exec team member, the administrative burden of managing multiple consultants, one for SR&ED, one for grants, and one for debt, can be overwhelming. Worse, it creates compliance risks. For example, claiming a grant for a project might inadvertently lower your SR&ED return if not modeled correctly. From our experience, an integrated partner ensures that accepting one form of capital does not disqualify the business from another, optimizing the "net benefit" of the entire stack.

Start a discovery call: Connect with us to help you map out the ecosystem partners relevant to your specific growth stage and industry vertical with our team to identify potential advisory or funding opportunities.

How to build a survival bridge with government capital

Building a survival bridge requires stacking non-dilutive funding sources, specifically prioritizing SR&ED, to extend runway without dilution. This process relies on understanding the technical criteria of each program to ensure compliance.

1. Understand SR&ED fundamentals: The Scientific Research & Experimental Development (SR&ED) program is a federal tax incentive defined under Section 37 of the Income Tax Act. Eligibility hinges on three key pillars: technological uncertainty, technological advancement, and systematic investigation. See the  CRA's eligibility guidelines  for detailed criteria.

2. Finance your receivables: By leveraging quarterly SR&ED financing to cover a portion of engineering payroll, companies can typically reduce their net cash burn. This converts a future tax credit into immediate cash flow.

3. Implement program stacking (SR&ED First): We strongly recommend companies first optimize their SR&ED claim before moving to other programs including something like IRAP. While stacking is possible, IRAP is considered government funding which reduces the SR&ED expenditure pool. Proper  cash flow modeling  is essential to ensure you are not "double-dipping" or eroding your tax credit value inefficiently.

4. Time your IRAP engagement: if you are going to engage with the NRC for a potential project, connecting with your Industrial Technology Advisor (ITA) at the start of the government fiscal year (March/April) is beneficial because that is when new pools of money are typically available.

5. Adopt integrated management: Utilizing an  integrated partner to manage the capital stack  ensures that grant applications align with program requirements and SR&ED claims are written in a highly defensible manner. This consistency is crucial if the Canada Revenue Agency (CRA) selects your file for review.

Strategic roadmap for 2026

A strategic roadmap for 2026 demands auditing your capital stack, prioritizing domestic entitlements, and maintaining contemporaneous documentation to secure non-dilutive funding. Founders must take control of their financial destiny by treating government capital as a core strategic asset.

FAQs

This section addresses common questions regarding venture debt, fundraising odds, and documentation requirements to help founders navigate the 2026 funding landscape.

Q: Is venture debt a viable option for early-stage startups?

A: Yes, it can be a viable option, specifically when secured against predictable assets such as SR&ED receivables or Annual Recurring Revenue (ARR).

Q: How does capital concentration affect my fundraising odds?

A: It suggests that fundraising is more competitive; non-dilutive funding is often a necessary alternative to bridge the gap until you fit the specific thesis of major funds.

Q: Why is documentation so critical for non-dilutive funding?

A: Programs such as SR&ED are retrospective; without strong contemporaneous evidence, claims are difficult to defend if selected for review by the CRA.

To discuss how these trends impact your specific runway and to explore your options, you can  survive the VC winter with government capital  by scheduling a consultation with our team.

‍